Le Lézard
Classified in: Health, Business
Subject: POL

Nation's Medical Specialists Demand Immediate End to Prior Authorization Abuse


WASHINGTON, Oct. 19, 2018 /PRNewswire/ -- A coalition comprised of the nation's major medical specialties is demanding that the Trump administration take immediate action to ensure patients' timely access to care. They are taking this action because patients are suffering from delays in care that are caused by the misuse of prior authorization requirements by Medicare Advantage plans.

AAO Logo (PRNewsFoto/American Academy of Ophthalmology)

The members of the Regulatory Relief Coalition are seeking to halt these abuses, the profound effect of which is evident in patients who receive regular injections to preserve vision as well as those who receive infusion treatments for crippling conditions.

Prior authorization is a tool that insurers use to reduce health care spending but often delays medically necessary treatments by forcing patients to obtain permission first.

Recent surveys by the American Medical Association and American College of Surgeons show how some insurance plans overuse this tool. One survey showed that on average, a medical practice will complete nearly 30 prior authorization requests for each physician every week. Each prior authorization takes about 15 hours to process. Following delays, requests are approved 90 to 100 percent of the time.

As a result, it is increasingly a prominent barrier to access that interferes with the physician-patient relationship.

"President Trump, it's time to reign in insurance companies whose misuse of prior authorization is threatening patients' outcomes," said Cathy G. Cohen, vice president for government affairs for the American Academy of Ophthalmology. "It won't take much ? just instruct Medicare Advantage plans on when and how prior authorization is to be used."

The coalition has championed this issue for more than a year. Its members have met with the Centers for Medicare & Medicaid Services leaders, the insurance industry, patient organizations, and Congress during that time. As a result, prominent patient advocacy groups ? including the Medicare Rights Center ? and Congress have joined this effort.

About the Regulatory Relief Coalition
The Regulatory Relief Coalition is a group of 10 national physician specialty organizations advocating for a reduction in Medicare program regulatory burdens so that physicians can spend more time with patients. 

American Academy of Dermatology Association ? American Academy of Neurology ? American Academy of Ophthalmology ? American Association of Neurological Surgeons ? American College of Cardiology ? American College of Rheumatology ? American College of Surgeons ? American Society of Clinical Oncology ? American Urological Association ? Congress of Neurological Surgeons

SOURCE American Academy of Ophthalmology; Regulatory Relief Coalition


These press releases may also interest you

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...

at 07:30
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...



News published on and distributed by: